SOURCE: Yasheng Group

August 22, 2005 16:10 ET

YaSheng Group's Biotech Science Research Center Patents Human DNA Technology That Is an Alternative to Antibiotics

REDWOOD CITY, CA -- (MARKET WIRE) -- August 22, 2005 --The YaSheng Group (OTC: YHGG) achieved a breakthrough in Lysozyme DNA Technology as reported by the company's Academy of Science Research and Development Center. YaSheng was awarded the patent for this newly developed technology under authorized patent (ZL03100582.9) and International patent (C12N15/62). If sold for $50/gram, YaSheng Group believes they can obtain annual sales of US $525,000,000 from this Patent.

Scientists at YaSheng Group reported that the Lysozyme they developed can eliminate Bacteria effectively without harmful side-effects; a great alternative to existing antibiotics which limits bacterial-growth. Lysozyme contains functions that strengthen the immune system, reduce inflammation and cell growth with demonstrated results in the prevention of oral cavity and respiratory tract.

The company reported a number of uses in this Lysozyme technology. Lysozyme can be used as an antiseptic for the food industry and serve as an essential additive to promote child growth. It can be utilized in baby food, powered formula and drinks. Adding Lysozyme to milk will make its characteristics closer to human milk. Furthermore, Lysozyme can also be utilized in dairy farming as a form of medication to prevent cow Mastitis. In the past, a common practice to handle cow Mastitis was through elimination and slaughter of herds, resulting in tremendous economic loss. Lysozyme had proven to be an effective treatment to eliminate cow mastitis.

The YaSheng Group Academy of Sciences Research and Development Center is in the process of applying Lysozyme DNA technology against Acquired Immune Deficiency Syndrome (AIDS HIV). This research had received strong support by the Chinese Government to further address the rising issue in China. Clinical medication for AIDS is typically expensive and is limited to only controlling the condition while contributing serious side effects. The scientific research team of YaSheng hopes to develop a new alternative for the treatment of (AIDS HIV-1) by creating cell activities which causes a high resistance to AIDS.

The market potential for Lysozyme is tremendous because of its flexibility, multiple applications and numerous benefits. It is not currently produced on an industrial level and is regarded highly by the bio-medical community. YaSheng plans to further enhance the development of Lysozyme and plans to utilize this new technology across a number of the company's subsidiaries. The company's pharmaceutical division had produced transgenic Lysozyme plants as an herbal and food product with strong properties in health. In addition, YaSheng will apply the new technology to agricultural fields for improvement of crop varieties and increase ability to resist bacteria in plants.

Additional uses for this patent can be viewed at:

http://www.yashenggroup.com/news_human_lysozyme.htm

About YaSheng Group:

The YaSheng Group (OTC: YHGG), a diversified industrial conglomerate incorporated in Redwood City, California, operates in hi-tech agriculture, salt chemistry and biological technology as its core business with advantages in land, mineral resources, capital and technology reserves.

Through its 136 subsidiaries, the company operating categories include: chemical engineering, agricultural production, biotech, pharmaceuticals, textile products, commercial trading, beverages and inorganic salt manufacturing. With total assets of approximately $1.5 billion USD and over 15,000 employees, YaSheng Group has 155,097,355 shares issued and outstanding as of December 1, 2004.

Further information concerning YaSheng Group can be found on the corporate website: www.yashenggroup.com

Forward-Looking Statements:

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.

Contact Information